Clinical Trial Update: Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) [Phase 2]

View source ↗

Summary

Phase 2 dose-response study evaluating safety and efficacy of beraprost sodium modified release in pulmonary arterial hypertension has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• beraprost sodium modified release (beraprost sodium modified release)

Snippet

Sponsor: Lung Biotechnology PBC | Conditions: Pulmonary Arterial Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2020-09-30